Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Myelomatosis therapy trial for patients of all age groups.

Next Previous
Trial Profile

Myelomatosis therapy trial for patients of all age groups.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Thalidomide (Primary) ; Thalidomide (Primary) ; Antineoplastics; Clodronic acid; Cyclophosphamide; Dexamethasone; Doxorubicin; Melphalan; Prednisolone; Prednisone; Vincristine; Zoledronic acid
  • Indications Graft-versus-host disease; Multiple myeloma; Osteolysis
  • Focus Therapeutic Use
  • Acronyms MRC-Myeloma-IX; Myeloma-IX

    • Most Recent Events

    • 16 Jan 2014 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network
    • 10 Dec 2012 Results of thalidomide maintenance according to biological risk groups presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
    • 17 Jun 2012 Long-term follow-up results for the zolendronic acid versus clodronic acid randomisation presented at the 17th Congress of the European Haematology Association.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top